Nascent Biotech director resigns; company faces OTC delinquency for late filing

Nascent Biotech Inc.

Douglas Karas resigned as independent director on Jan 10, 2025 due to personal health issues.
Company received OTC delinquency for untimely filing; will file Q3 2025 (likely Q3 2024) to maintain pink sheet status.
Directors and officers agreed to terminate non-dilutive stock clause in employment contracts.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Douglas Karas

independent Director

Nascent Biotech Inc.

Effective: 2025-01-10
Filed: January 17, 2025, 6:59 PM ET

On January 10, 2025, Douglas Karas submitted his written resignation as an independent Director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Douglas Karas resigned as independent Director at Nascent Biotech Inc..

Action: resigned
Role: independent Director

Exact text from the filing

On January 10, 2025, Douglas Karas submitted his written resignation as an independent Director of the Company.

View on SEC.gov

Source: SEC EDGAR

accession 0001477932-25-000328

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.